Project: A 99mTc-labeled Radiopharmaceutical for the Imaging of hypoxia and of renal cell carcinoma

We want to develop a best-in-class radiopharmaceutical product for the imaging of hypoxia and of renal cell carcinoma in cancer patients. This product will enable more informed decisions for the management of the patients and should find a broad applicability in Clinical Oncology. Carbonic anhydrase IX (CAIX), arguably the best marker of hypoxia and of renal cell carcinoma, has so far been imaged using antibodies. Our proprietary CAIX ligand outperforms other products in industrial development.

Acronym	ATRI (Reference Number: 9669)
Duration	01/10/2015 - 01/10/2017
Project Topic	Other Industrial Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 3

Project partner

Number	Name	Role	Country
21261	Philochem AG	Coordinator	Switzerland
21262	Medical University of Vienna Department of Biomedical Imaging and Image-guided Therapy Division of Nuclear Medicine	Partner	Austria